Skip to content

The clinical and neuromechanisms research for Shizhen Anshen granules treatment on cognitive impairments of first episode schizophrenia

The clinical and neuromechanisms research for Shizhen Anshen granules treatment on cognitive impairments of first episode schizophrenia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032877
Enrollment
Unknown
Registered
2020-05-14
Start date
2020-07-01
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Sponsors

Beijing Anding Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the criteria of first-episode schizophrenia stipulated in the study; 2. Patients aged 18-40 (including 18 and 40 years old); 3. Patients who voluntarily sign the informed consent and are able to follow the research program; 4. Patients who can understand the follow-up questionnaire; 5. Patients who meet the criteria of syndrome type of kidney yin deficiency and fire hyperactivity of TCM in psychiatry (hallucination, delusion, weird thinking, scattered thinking, dull and little speech, self talk and self laugh, alone in a corner, sore waist and knees, dry mouth, constipation, red tongue, little moss, teeth marks, fine pulse strings).

Exclusion criteria

Exclusion criteria: 1. Objects with serious suicidal tendencies; 2. Patients with depressive episode; 3. Patients with serious or unstable heart, liver, kidney, endocrine, blood and other medical diseases; 4. The patients who took antipsychotic drugs in the first 4 weeks were selected; 5. Patients without supervision; 6. Patients with PANSS score reduction rate >= 25% at baseline compared with those at screening.

Design outcomes

Primary

MeasureTime frame
cognitive function;P300, PPI;

Secondary

MeasureTime frame
symptoms assessment;functional connectivity;

Countries

China

Contacts

Public ContactYanzhe Ning

Beijing Anding Hospital Affiliated to Capital Medical University

yanzhening0923@163.com+86 10-58303065

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026